Holders — by stockHoldings — by fund
Sands Capital Alternatives, LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-09-30 · filed with the SEC up to 45 days after quarter end · CIK 0001846444
$694.7M
disclosed book value
24
positions
20.7%
largest position share
Positions, as of 2026-09-30
top 24 of 24 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | ALMRALAMAR BIOSCIENCES INC | 4.2M | $144.1M | 20.7% |
| 2 | NUNU HLDGS LTD | 7.0M | $88.5M | 12.7% |
| 3 | BBNXBETA BIONICS INC | 4.0M | $75.9M | 10.9% |
| 4 | SGPSPYGLASS PHARMA INC | 2.5M | $65.0M | 9.4% |
| 5 | KVYOKLAVIYO INC | 3.8M | $60.2M | 8.7% |
| 6 | TXG10X GENOMICS INC | 481,770 | $43.5M | 6.3% |
| 7 | IKTINHIBIKASE THERAPEUTICS INC | 13.0M | $26.8M | 3.9% |
| 8 | CBRSCEREBRAS SYSTEMS INC | 122,484 | $21.8M | 3.1% |
| 9 | DASHDOORDASH INC | 107,301 | $19.7M | 2.8% |
| 10 | ODTXODYSSEY THERAPEUTICS INC | 875,000 | $19.4M | 2.8% |
| 11 | FRNMFREENOME INC | 1.2M | $18.9M | 2.7% |
| 12 | CPNGCOUPANG INC | 1.2M | $17.3M | 2.5% |
| 13 | DDOGDATADOG INC | 63,020 | $17.3M | 2.5% |
| 14 | IOTSAMSARA INC | 395,621 | $15.1M | 2.2% |
| 15 | TOSTTOAST INC | 314,907 | $9.1M | 1.3% |
| 16 | ABOSACUMEN PHARMACEUTICALS INC | 3.7M | $8.3M | 1.2% |
| 17 | SNOWSNOWFLAKE INC | 22,926 | $7.8M | 1.1% |
| 18 | TARSTARSUS PHARMACEUTICALS INC | 85,000 | $6.7M | 1% |
| 19 | TTANSERVICETITAN INC | 91,101 | $6.0M | 0.9% |
| 20 | BIOABIOAGE LABS INC | 786,353 | $5.6M | 0.8% |
| 21 | MNDYMONDAY COM LTD | 67,182 | $5.3M | 0.8% |
| 22 | ACRVACRIVON THERAPEUTICS INC | 2.3M | $4.7M | 0.7% |
| 23 | CADLCANDEL THERAPEUTICS INC | 405,837 | $4.2M | 0.6% |
| 24 | TSHATAYSHA GENE THERAPIES INC | 724,873 | $3.5M | 0.5% |
Source: SEC Form 13F-HR, reporting period 2026-09-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.